<DOC>
	<DOCNO>NCT01652703</DOCNO>
	<brief_summary>The primary objective evaluate effect 12 week subcutaneous evolocumab every 2 week every 4 week , compare placebo , percent change baseline low-density lipoprotein cholesterol ( LDL-C ) use addition statin therapy Japanese adult hypercholesterolemia high cardiovascular risk .</brief_summary>
	<brief_title>A Study Evaluate Tolerability Efficacy Evolocumab ( AMG 145 ) Japanese Subjects</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<criteria>Japanese adult , statin , without ezetimibe , stable dose ( ) least 4 week , fast LDLC great equal 115 mg/dL ( 3.0 mmol/L ) , fast triglyceride less equal 400 mg/dL ( 4.5 mmol/L ) ; Exclusion Criteria : New York Heart Association ( NYHA ) class III IV , poorly control hypertension , recently diagnose poorly control type 2 diabetes , last known leave ventricular ejection fraction &lt; 30 % , myocardial infarction , unstable angina , percutaneous coronary intervention ( PCI ) , coronary artery bypass graft ( CABG ) , stroke , plan cardiac surgery revascularization within 6 month randomization , uncontrolled cardiac arrhythmia .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Japanese , hypercholesterolemia , high risk cardiovascular event</keyword>
</DOC>